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A Comparative Analysis of Major Clinical Outcomes with Drug-Eluting Stents
versus Bare Metal Stents in Male versus Female Patients
Ran Kornowski, Hana Vaknin-Assa, Abid Assali, Eli I Lev, Danny Dvir, Avital Porter,
Alexander Battler, Tamir Bental
Rabin Medical Center, Petah-Tikva, Israel
Background: The impact of different types of stents on clinical outcomes is of great
interest because coronary disease is a major cause of morbidity and mortality for both
genders. This study aimed to conduct a risk-adjusted gender-based analysis of clinical
outcomes following drug-eluting stent (DES) versus bare metal stent (BMS)
implantation in patients with coronary artery disease.
Methods: We compared risk-adjusted total mortality rate, myocardial infarction, and
event-free survival in a consecutive cohort of 7,662 patients undergoing percutaneous
coronary intervention at our institution, including 1835 (25.4%) women. Follow-up
was 6 months to 6.2 years (mean 3.5 years, median 3.6 years).
Results: Women were older than men and more likely to suffer from diabetes,
hypertension, or congestive heart failure. Smokers were more often men, and men were
more likely to have had prior coronary bypass surgery compared to women. A DES
was used in 39.9% of males and 39.5% of females. Both genders derived a significant
long-term clinical benefit from DESs compared to BMSs; advantages were observed
for mortality (men: HR=0.78, 95% CI: 0.64 - 0.96, p=0.016; women: HR=0.62, 95%
CI: 0.45 - 0.85, p=0.003) and major adverse cardiac events (men: HR=0.73, 95% CI:
0.63-0.84, p<0.001; women: HR=0.76, 95% CI: 0.52-0.84, p=0.001). Among BMS-
treated patients, women had worse cumulative clinical outcomes than men. DESs
eliminated the gender differences in cardiac prognosis.
Conclusion: Our analysis indicated a profound prognostic advantage for DESs versus
BMSs among both genders, though female patients appeared to derive the greatest
benefit.
TCT-205
The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON)
Compared with Different Polymer Based Drug-Eluting Stents in Real-World
Coronary Artery Lesions
Ted Spase Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski
Spitali Zemres, Prishtina, Albania
Background: We compared the safety and efficacy of different permanent polymer
based drug-eluting stents (PBS) with a polymer-free drug-eluting stent (PFS-Yukon).
In unselected real-world patients with coronary lesions of various complexities, we
retrospectively compared both stent designs.
Methods: A total of 617 lesions in patients with symptomatic CAD were treated with
PBS (n = 383) or with PFS (n = 234). The PBS group consisted of 44(12%) Cypher,
101(26%) Xience, 107(28%) Endeavor, 55(14%) Infinium and 75(20%) Coroflex
Please stents, assigned to patients and lesions by shelf disposal and target vessel
dimensions. The primary clinical endpoint of this study was a composite of cardiac
death, myocardial infarction and clinical-indicated target vessel revascularisation
(MACE).
Results: Follow-up was obtained in 98,2% of patients. All patients were treated with
clopidrogrel and aspirin during follow up. Polymer free stents were non-inferior to
polymer- stents for the primary endpoint at 9 months (13 [5.6%] vs 21 [5.5%], HR:
0.98 [95% CI 0.48-2.01], p for superiority=0.96). Frequency of cardiac death (5 [2.1%]
vs 6 [1.6%], p for superiority=0.41), myocardial infarction (4 [1.7%] vs 16 [4.2%],
p=0.07), and clinically-indicated target vessel revascularisation (8 [3.4%] vs 18 [4.7%],
p=0.29) were similar for both stent types. Analysis of MACE after 9 months resulted
in 4 (1.7%) definitive stent thrombosis causing MI in PFS vs. 18(4.7%) in PBS treated
lesions, with borderline significant difference (log rank, p=0.052). In the cox
proportional regression analysis of MACE, none of the stents showed different survival
according to stratification by presence of Diabetes, ST-elevationMI, multivessel
disease, Left anterior, long or small vessel lesions, (p=0.93; p=0.97; p=0.99; p=0.95;
p=0.96; p=0.85), respectively.
Conclusion: Up to 9 months after PCI of real-world coronary lesions, there were no
statistically significant differences in MACE between lesions treated with the polymer-
free YUKON stent and the group of polymer-based stents.
TCT-206
Real-World Comparison Of Clinical Outcomes Of Patients Who Received New
Generation Platinum Chromium Everolimus-Eluting Stent Versus Cobalt
Chromium Everolimus-Eluting Stent
Ruogu Li, Adrian F Low, Chi Hang Lee, Mark Chan, Swee Guan Teo, Koo Hui
Chan, Arthur Mark Richards, Huay Cheem Tan
cardiac, National University Heart Centre, Singapore, Singapore
Background: The safety and efficacy of the first generation cobalt chromium
everolimus-eluting stent (EES) have been demonstrated in several trials. The PROMUS
Element (Boston Scientific, Natick, Massachusetts) stent is a new generation EES,
made of platinum chromium alloy with thin strut designed to improve radial strength,
radiopacity, vessel conformability, fracture resistance, side-branch access and
deliverability. We aim to compare the safety and efficacy of this novel PtCr-EES with
the first generation cobalt chromium EES (CoCr-EES) in patients who received them.
Methods: We analyzed retrospectively 805 patients who received PtCr-EES(n=391)
or CoCr-EES (n=414) from our centre cardiovascular database. The primary endpoint
was the 6-month composite major adverse cardiac events (MACE) that include cardiac
death, myocardial infarction, target vessel revascularization and stent thrombosis.
Results: The mean age of the cohort was 58.7±10.1 years with males constituting
82.7%. Diabetes mellitus was present in 322 (40.0%) patients. The majority (63.1%)
of the lesions treated were of AHA/ACC Type B2/C. The mean lesion length in the 2
groups were 26.14±12.19 mm (PtCr-EES) vs 24.14±11.86 (CoCr-EES), p=0.009
respectively; and the stent length were 31.27±14.38mm (PtCr-EES) vs 31.23±14.61mm
(CoCr-EES), p=0.96 respectively. At 6 months, the results were as follow:
Clinical Outcome
Conclusion: Our study showed that PtCr-EES stent, when used in real-world
population, showed similar medium-term efficacy as the first generation EES with no
safety concerns related to the novel stent material and design. The TVR rate is low at
<2% for both groups.
TCT-207
Interim Analysis of the IMOS - MGUARDTM International Registry
Chaim Lotan1, Alex Abizaid2, Apro Dezso3, Jan Horák4, Gian B Danzi5, Miriam
Ivenshitz6
1Hadassah University Medical Center, Jerusalem, Israel; 2Institute Dante Pazzanese
of Cardiology, Sao Paulo, Brazil; 3State Hospital for Cardiology Balatonfüred,
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Background: Despite the success of percutaneous intervention along with stent
deployment in opening up an occluded coronary artery in AMI patients, the
phenomenon of distal embolization may result in impaired myocardial perfusion and
myocardial recovery and remains a significant concern in reperfusion therapy. The
MGUARDTM stent (InspireMD, Tel Aviv, Israel) comprises a mesh which is wrapped
around a balloon-expandable, bare metal stent. The mesh is designed to trap thrombus
and fragile plaque against the vessel wall and prevent them from entering the lumen
thereby preventing distal embolization. The IMOS (International MGUARD
Observational Study) Registry enrolled consecutive patients treated with the
MGUARDTM stent with the objective to evaluate its clinical performance and safety.
Methods: The IMOS registry is a prospective, non-randomized, single arm,
multinational, observational study designed to enroll 1000 patients. Angiographic
exclusion criteria include heavily calcified lesions and large side branches. The primary
endpoint is MACE at 6 months. Patients are evaluated at 1, 6 and 12 months.
Results: A total of 382 patients who matched the inclusion/exclusion criteria have been
enrolled to date, and were sorted into groups according to clinical presentation and
number and type of stent deployed. A group of 203 patients (53.0% of patients enrolled
in the registry), who presented with STEMI and in whom only MGUARDTM was
implanted, were analyzed and are presented here. 43.6% of these patients suffered from
hyperlipidemia, 59.4% from hypertension and 15.3% from diabetes. 8.0% had prior
PCI and 9.9% had previous MI. The culprit lesion was in the RCA in 49.7% of cases
and in the LAD in 36.2%. A visible thrombus was seen in 98.0%. In 41%, thrombus
aspiration was used. Procedure success was 98.0% and final TIMI3 flow was achieved
in 93.5% of patients. At 30 days, 6 months and 1 year, MACE rates were 2.4%, 3.2%
and 6.0% respectively.
Conclusion: PCI with MGUARDTM represents an efficient and safe approach in
treating STEMI patients, with low rates of MACE and high rates of procedure and
angiographic success.
TCT-208
Late Clinical Impact of Postprocedural Incomplete Stent Apposition and Late
Acquired Incomplete Stent Apposition After Deployment of Zotarolimus
Eluting Stent or Everolimus Eluting Stent
Sang-Rok Lee1, Jei-Keon Chae1, Shin-Eun Lee2, Jong-Pil Park2, Kyeong-Ho Yun3,
Young-Joon Hong4, Jay-Young Rhew2, Seok-Kyu Oh3, Jae-Ki Ko1
1Cardiology, Chonbuk National University Hospital, Jeonju, Republic of Korea;
2Presbyterian Medical Center, Jeonju, Republic of Korea; 3Wonkang University
Hospital, Iksan, Republic of Korea; 4Chonnam National University Hospital,
Gwangju, Republic of Korea
Background: There has been limited data regarding the late clinical impact of post-
procedural incomplete stent apposition (PISA) and late incomplete stent apposition
(LISA) in the newer generation of drug eluting stent. The aim of this study was to
investigate the incidence of LISA and change of PISA during follow up.
Methods: We prospectively enrolled 101 patients who underwent percutaneous
coronary intervention (PCI) in de novo coronary lesions; stable angina (n=26), unstable
angina (n=61), and non-ST segment elevation myocardial infarction (n=13) (62.2±8.8
years, 72 male, 121 lesions). The group was randomly assigned (proportion of 2:1) to
zotarolimus eluting stent (group I, n=81, Endeavor Resolute, Medtronic, MN) or
everolimus eluting stent (group II, n=40, Xience V, Abbott Vascular, Illinois). Post-
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PCI and follow up intravascular ultrasound (IVUS, mean 9.9±2.4 months) were
performed in all patients.
Results: The Post-PCI external elastic membrane (EEM) volume (group I vs group II,
417.3±196.5 vs 409.7±180.1 mm3, p=NS), post-PCI lumen volume (228.6±111.0 vs
223.0±89.5 mm3, p=NS), follow up EEM volume (435.1±168.1 vs 414.9±179.4 mm3,
p=NS), and follow up lumen volume (236.6±91.7 vs 222.5±90.1 mm3, p=NS) by IVUS
were not different between the two groups. There were three LISAs [2.5%, group I
(n=2) vs group II (n=1)] and thirty four PISAs [28.1%, group I (n=23) vs group II
(n=11)] that were resolved [14.7%, group I (n=4) vs group II (n=1)]. Post-PCI and
follow up volume of PISA was not significantly different in both group I (5.9±5.6 vs
5.1±4.6 mm3, p=NS) and group II (8.9±4.4 vs 8.5±4.2 mm3, p=NS). There was no
major adverse cardiac event associated with LISA or PISA during 12-month clinical
follow up.
Conclusion: The incidence of LISA was very low in both groups comparing to the
previous generation of drug eluting stent. Both LISA and PISA were not associated
with cardiac events during 12-month follow up. Future long-term follow up study to
clarify the clinical impacts of LISA and PISA would be needed.
TCT-209
Drug Eluting Stents in the Treatment of Isolated Proximal LAD Disease are
Associated with Similar Outcomes Compared to Minimally Invasive LIMA
Grafts
Daniel A Jones, Krishnaraj S Rathod, Sean M Gallagher, Zia Buckhoree,
Mohammed Akhtar, Ajay K Jain, Charles Knight, Anthony Mathur, Rakesh Uppal,
Andrew Wragg
Department of Cardiology, Barts and the London NHS Trust, London, United
Kingdom
Background: We studied the long term outcome of patients with isolated proximal
LAD disease revascularised with either DES or ‘off-pump’ left internal mammary
artery (LIMA) graft.
Methods: 874 consecutive patients with stable angina undergoing either elective
percutaneous coronary intervention with a DES or ‘off-pump’CABG for significant
isolated proximal LAD disease at a London centre between Oct 2003-December 2010
were studied. The primary end point used was major adverse cardiac events (MACE),
defined as the composite of death, myocardial infarction (MI), stroke and target vessel
revascularization (TVR).
Results: 752 patients underwent PCI with DES and 122 pts underwent ‘off-pump’
CABG. The baseline demographic and angiographic characteristics were similar
between the two groups. The mean duration of hospitalization after CABG was 6.33
± 1.61 days vs. 1.06 ± 0.20 days after PCI (P < 0.001). Kaplan-Meier estimates of
major adverse cardiac events showed no differences between the groups over the
follow-up period (11.8% vs 12.0%, p=0.9 at 4 years) (Figure 1a). On MACE
breakdown there was a trend towards higher mortality in the LIMA cohort (7.8% vs
4.2%, p = 0.12) with a trend towards higher TVR in the DES group (5.8% vs 2.8%,
p=0.19) (Figure 1b). After multivariate adjustment revascularisation technique was not
predicative of major-adverse cardiac events.
Conclusion: The study demonstrated that DES have similar long-term results to LIMA
regarding MACE events in patients with isolated proximal LAD disease.
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Low Incidence of Stent Thrombosis in Asian Races: Multicenter Registry in
Asia 6 Years Follow-Up Result
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Udayachalerm5, Damras Tresukosol6, Sudaratana Tansuphaswadikul7
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Thailand; 6Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand; 7Chest Disease Institute, Nontaburi, Thailand
Background: The aim of this study was to evaluate the frequency, predictors and the
clinical outcome of stent thrombosis after DES implantation and bare metal stent
(BMS) implantation in Asian races.
Methods: A total of 14,577 consecutive patients who underwent successful DES
implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38%
of the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients)
were included in this study. We evaluate the frequency, predictor of stent thrombosis.
Results: At a mean follow-up of 78.5±29.9 months in DES and 81.8±26.4 months in
BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis
(SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18%
with DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year
with DES and no BMS. Independent predictors of stent thrombosis are bifurcation
lesion (OR=1.90, 95% CI: 1.83 to 24.24, p=0.01) and ejection fraction (OR=0.90, 95%
CI: 0.86 to 0.94, p=0.03). Only 0.2 % of the patients were died because of the
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